This collection features innovative companies revolutionizing healthcare by developing treatments tailored to individual genetic profiles. Carefully selected by our analysts, these stocks represent the cutting edge of precision medicine, where customized therapies aim to deliver more effective patient outcomes.
Personalized medicine is rewriting healthcare's rulebook. These companies are at the forefront of a revolution that could make traditional treatments obsolete while creating entirely new markets.
Recent regulatory approvals for gene therapies are accelerating the path to market. As more personalized treatments gain validation, these pioneering companies could see rapid adoption and growth.
Imagine treatments designed specifically for your genetic code. These companies are making this a reality, potentially capturing massive value as healthcare shifts toward precision therapies with better outcomes.
The healthcare industry is shifting from one-size-fits-all treatments to therapies designed for specific genetic profiles. Companies in this collection are pioneering technologies that target diseases at their molecular source, potentially offering more effective treatments with fewer side effects.
This portfolio includes companies at various stages of innovation—from diagnostic tools to therapeutic development. Consider this an aggressive growth component for your investments, as many firms are still developing commercial pathways for their technologies.
These companies were selected for their leadership in genomic sequencing, biomarker discovery, and targeted therapies like CRISPR gene editing. Recent regulatory approvals for gene-specific treatments and AI advancements in drug discovery provide significant growth catalysts.
Aggregate market capitalisation and investor takeaways for the provided basket.
PSNL: $848.64M
PRME: $977.47M
EDIT: $348.89M
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
BHP Group recently posted a massive earnings beat driven by record copper profitability, allowing the miner to raise its dividend to a four-year high. This performance highlights a structural shift toward electrification metals, creating opportunities for industrial equipment suppliers and competing copper producers.
+6
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+163.39%
On average, analysts expect assets in this group to grow 163.39% over the next year.
14 of 16 assets in this group are rated Buy by professional analysts.
